Progress Software Corporation
(NASDAQ: PRGS), a global software company that simplifies and enables the development and deployment of business applications, today announced that
, a leading provider of
Electronic Health Records
(EHR) for dialysis centers and the renal industry, has chosen the new
11.2 application development platform, featuring the
OpenEdge Mobile product
to help its clients save time and improve quality of care. Using the new solution, Infian will now be able to make data available securely - where it’s needed and when it’s needed - using the latest in mobile technology.
Infian has been in the healthcare business for over 30 years and has worked with Progress Software to develop comprehensive EHR solutions. As the industry has evolved into its current cloud, mobility and “bring your own device” environments, Infian is using the OpenEdge 11.2 platform to develop solutions to help medical centers and physician offices easily and securely manage patient care while remaining compliant.
earlier this month at the
Progress Software Global Partner Conference
and now generally available, the OpenEdge 11.2 platform with the Progress OpenEdge Mobile product provides developers with a quick and easy way to deploy full enterprise applications on mobile operating systems, including iOS and Android, while also taking advantage of mobile device features. This “write once, run anywhere” approach helps organizations bridge the so-called
mobile app gap
By leveraging the powerful back-end capabilities of the OpenEdge platform, it can increase developer productivity by 40% or more compared to time-consuming, feature-limiting competitive solutions. The OpenEdge Mobile product allows developers to continuously and efficiently update applications as the mobile market evolves and new devices are introduced. As a result, developers have a highly productive, simplified development experience from start to finish from which they can integrate end-user access to full features of critical business applications on mobile devices.